because of it high recurrence rate and disease progression. FGFR3 mutation in bladder

cancer is associated with non muscle invasive and low grade disease this making it a non

invasive marker of for nonaggressive disease.

 

AIM:  The  aim  of  this  study  was  to  detect FGFR3  mutation  in  a  single  voided urine

sample of bladder cancer patients in Indian population and its diagnostic and prognostic

performance.

 

MATERIALS AND METHOD: A prospective observational study was carried out with

one–year follow–up of primary bladder tumor patients . Urine samples were collected

before TURP. Screening for the most prevalent FGFR3 mutations was done using urinary

cells. The prognostic significance of an FGFR3 mutation at the time of the initial

diagnosis was determined. The performance of the test in diagnosing and/or predicting

recurrence during follow up was assessed .

 

RESULTS: Of 39 patients studied, 2 (5.62%) had a positive analysis before TUR

(FGFR3 MT). There was no statistical significance between MT and WT when compared

with  grade and stage of tumor. Neither there was any significant risk of tumor recurrence

and progression in FGFR3 mutated as compared to wild  type group.

 

Conclusion: Among patients with an FGFR3 mutation in the initial tumor, a

noninvasive urine test from a single voided sample before primary resection cannot be

valuable in diagnosing or predicting subsequent recurrence or progression.